XCT0135908
XCT0135908 (XCT) is a selective Nurr1-RXRα activator with an EC50 value of 0.3 μM in human dopaminergic SH-SY5Y cells. XCT0135908 protects dopaminergic cells against the Parkinson’s disease-related toxin MPP+. XCT0135908 can be used for the research of Parkinson’s disease.
Para uso exclusivo en investigación. No vendemos a pacientes.
- No. CAS: 300837-31-4
- Fòrmula: C21H19N3O2
- Peso molecular:345.40
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
Ver todos los productos específicos de isoformas Nuclear Hormone Receptor 4A/NR4A
More
Actividad biológica
Descripciòn
In Vitro
XCT0135908 (Compound 7a) (0.5-12.5 μM; overnight) activates the Nurr1-RXRα heterodimer in human dopaminergic SH-SY5Y cells with an EC50 of 0.3 μM[1].
XCT0135908 (0.5-12.5 μM; 12 h) selectively activates Nurr1-RXRα and Nur77-RXRα heterodimers (but not other RXRα heterodimers or homodimers) in human dopaminergic SH-SY5Y cells, with greater activation of Nur77GAL4-RXRαVP16 than Nurr1GAL4-RXRαVP16[1].
XCT0135908 (12.5-50 μM) protects mouse Neuro-2a neuroblast cells from MPP+-induced toxicity at concentrations of 12.5 μM and 50 μM, with no observed toxicity at 50 μM[1].
XCT0135908 (0.5-12.5 μM; 24 h) induces a moderate concentration-dependent increase in SREBP-1c expression in human HepG2 hepatic cells, with a maximal ~5-fold increase at 12.5 μM[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:human HepG2 hepatic cells
-
Concentration:0.5 μM; 12.5 μM
-
Incubation Time:24 h
-
Result:Triggered a concentration-dependent increase in SREBP-1c expression.
Induced a maximal increase of ~5-fold over controls.
Chemical Information
-
No. CAS 300837-31-4
-
Peso molecular 345.40
-
Fòrmula C21H19N3O2
-
SMILES
O=C(O)C1=CC=C(C=C1)NC2=NC(=NC(=C2CC=C)C)C=3C=CC=CC3
-
Synonyms
XCT
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocolo
-
Ferroptosis Solutions
Ferroptosis is an iron-dependent, non-apoptotic form of regulated cell death characterized by lethal lipid peroxidation and sensitivity to suppression by iron chelators or lipophilic radical-trapping antioxidants. The core pathway links cystine uptake through system Xc−, glutathione availability, GPX4-dependent detoxification of phospholipid hydroperoxides, iron-dependent oxidative reactions, and polyunsaturated-phospholipid metabolism into a cell-death program that is biochemically and morphologically distinct from apoptosis, necrosis, and autophagy. The ferroptosis pathway is experimentally linked to phenotype through chemical and genetic perturbation. Erastin induces ferroptosis by inhibiting cystine uptake through system Xc− and weakening antioxidant defenses, while GPX4 inhibition or depletion causes lipid peroxide accumulation and ferroptotic cancer-cell death. ACSL4 and oxidizable arachidonoyl- or adrenoyl-containing phosphatidylethanolamines shape ferroptosis sensitivity by con
Pureza y Documentación
Referencias
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)